ATE114476T1 - Tierische zelle mit darin eingeführtem antigenem protein. - Google Patents

Tierische zelle mit darin eingeführtem antigenem protein.

Info

Publication number
ATE114476T1
ATE114476T1 AT88109455T AT88109455T ATE114476T1 AT E114476 T1 ATE114476 T1 AT E114476T1 AT 88109455 T AT88109455 T AT 88109455T AT 88109455 T AT88109455 T AT 88109455T AT E114476 T1 ATE114476 T1 AT E114476T1
Authority
AT
Austria
Prior art keywords
cells
modified
aids
virus
erythrocytes
Prior art date
Application number
AT88109455T
Other languages
English (en)
Inventor
Yves C Nicolau
Garret M Ihler
Original Assignee
Hapgood C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE114476(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hapgood C V filed Critical Hapgood C V
Application granted granted Critical
Publication of ATE114476T1 publication Critical patent/ATE114476T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT88109455T 1987-06-30 1988-06-14 Tierische zelle mit darin eingeführtem antigenem protein. ATE114476T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6828887A 1987-06-30 1987-06-30
US19744588A 1988-05-27 1988-05-27

Publications (1)

Publication Number Publication Date
ATE114476T1 true ATE114476T1 (de) 1994-12-15

Family

ID=26748809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88109455T ATE114476T1 (de) 1987-06-30 1988-06-14 Tierische zelle mit darin eingeführtem antigenem protein.

Country Status (9)

Country Link
US (1) US5677176A (de)
EP (1) EP0298280B1 (de)
JP (2) JP2728166B2 (de)
AT (1) ATE114476T1 (de)
AU (2) AU1821988A (de)
CA (1) CA1327332C (de)
DE (1) DE3852221T2 (de)
ES (1) ES2067457T3 (de)
IL (1) IL86650A0 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
CA1327174C (en) * 1988-10-05 1994-02-22 Youssef Mouneimne Electro-insertion of proteins into animal cell membranes
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
JPH04502168A (ja) * 1988-12-22 1992-04-16 ザ　ダウ　ケミカル　カンパニー 複素環式ポリマーの改良合成方法
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
ES2081502T3 (es) * 1990-10-19 1996-03-16 Univ Florida Envolturas viricas artificiales.
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
ATE157879T1 (de) * 1991-06-14 1997-09-15 Europ Communities Transformierte erythrozyten, verfahren zu deren herstellung, und ihre verwendung in pharmazeutischen zusammensetzungen
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
DE69329145D1 (de) * 1992-03-11 2000-09-07 Kenneth Francis Prendergast Anti-virale Fusionspeptide
WO1994004677A1 (en) * 1992-08-13 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of cd4 plasma membrane vesicles (pmv) as a therapeutic agent for aids
WO1994006903A1 (en) * 1992-09-22 1994-03-31 Dnx Biotherapeutics, Inc. Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
IL114520A0 (en) * 1994-07-15 1995-11-27 Lepetit Spa Dinucleoside-5',5',-pyrophosphates
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
WO2000029556A2 (en) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
CZ20012038A3 (cs) 1998-12-23 2001-09-12 Idea Ag Zdokonalený přípravek pro topické, neinvazivní použití in vivo
EP1031346B1 (de) 1999-01-27 2002-05-02 Idea Ag Nichtinvasive Impfung durch die Haut
EP1031347B1 (de) 1999-01-27 2002-04-17 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
EP1921451A3 (de) * 2001-05-22 2008-05-28 Cygene, Inc. Komplement-vermittelte Assays für In-vivo- und In-vitro-Verfahren
DE60233885D1 (de) 2001-10-16 2009-11-12 Kode Biotech Ltd Aus modifizierten zellen präparierte empfindlichkeitskontrollen für blutserologie
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
KR20100127842A (ko) * 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
WO2011044369A1 (en) 2009-10-08 2011-04-14 Otsuka Pharmaceutical Co., Ltd. An immunoactivation blood perfusion filter for the treatment of malignant tumors
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
FR2564319A1 (fr) * 1984-05-21 1985-11-22 Inst Nat Sante Rech Med Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes

Also Published As

Publication number Publication date
AU1821988A (en) 1989-04-27
AU1942692A (en) 1992-09-24
JP2728166B2 (ja) 1998-03-18
CA1327332C (en) 1994-03-01
JPH01124382A (ja) 1989-05-17
JPH1072368A (ja) 1998-03-17
DE3852221D1 (de) 1995-01-12
JP2825804B2 (ja) 1998-11-18
ES2067457T3 (es) 1995-04-01
IL86650A0 (en) 1988-11-30
DE3852221T2 (de) 1995-04-06
EP0298280B1 (de) 1994-11-30
AU662154B2 (en) 1995-08-24
EP0298280A3 (en) 1990-05-02
US5677176A (en) 1997-10-14
EP0298280A2 (de) 1989-01-11

Similar Documents

Publication Publication Date Title
AU662154B2 (en) Animal derived cell with antigenic protein introduced therein
Murphy The neutrophil
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
ES8503951A1 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
DE69033700D1 (de) Il-11 aus säugetier
ATE110412T1 (de) Translation von mrna.
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
CA2104396A1 (en) Viral particles having altered host range
DK163683D0 (da) Fremstilling af funktionelle humane urokinaseproteiner, dna-sekvens, der koder for et protein omfattende den enzymatiske del af human urokinase, replicerbart udtrykkelsesmedium, der kan udtrykkedna-sekvensen og mikroorganisme eller cellekultur transformeret med mediet
AU6804987A (en) Method for treating plasma and products thereof
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
ATE103982T1 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DE3061854D1 (en) Process for the preparation of interferon and culture medium composition used in it
GR3007031T3 (de)
DK266083A (da) Fremgangsmaade til fremstilling af 2-heterocyclyl-1,3-bis(1h-1,2,4-triazol-1-yl)propan-2-oler eller farmaceutisk acceptable syreadditionssalte deraf
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
DE3268160D1 (en) Medicaments based on algae, and formulations thereof
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
EP0278487A3 (de) Verfahren zur Inaktivierung hüllhaltiger Viren in mittels einer Zelle in vitro hergestellten Protein-Präparationen
IT8621230A1 (it) Policarbonati ramificati contenenti acidi alifatici policarbossilici o loro derivati e procedimento per la loro preparazione
DK373489A (da) Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler
RU94045821A (ru) Трансгенные растения, проявляющие множественную устойчивость к вирусу, и способ их получения
Iwata et al. Identification of human H‐Y antigen and its testis‐organizing function
ES8800275A1 (es) Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution
REN Ceased due to non-payment of the annual fee
REN Ceased due to non-payment of the annual fee